SCHEMBL6984103

SCHEMBL6984103

CC(C)C[C@@H](CO)NC(=O)[C@@H](NS(=O)(=O)c1ccc2ccccc2c1)C(C)C

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 2/20 0.55
LARS1 Q9P2J5 1/20 0.55
SLC1A3 P43003 1/20 0.49
SLC1A2 P43004 1/20 0.49
SLC1A1 P43005 1/20 0.49
ADAMTS4 O75173 2/20 0.46
MMP13 P45452 2/20 0.46
MMP1 P03956 2/20 0.45
MMP2 P08253 1/20 0.45
MMP3 P08254 1/20 0.45
MMP7 P09237 1/20 0.45
MMP9 P14780 1/20 0.45
CAPN1 P07384 2/20 0.45
CTSB P07858 2/20 0.45
ALDH1A1 P00352 2/20 0.42
F2 P00734 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27486757 1.00 ADAM17 (0.55) ADAM17LARS1SLC1A3SLC1A2SLC1A1
SCHEMBL3915375 0.84 CAPN1 (0.64) ADAM17LARS1SLC1A3SLC1A2SLC1A1
SCHEMBL6976052 0.82 CAPN1 (0.56) SLC1A3SLC1A2SLC1A1ADAMTS4MMP13
SCHEMBL3840645 0.82 CAPN1 (0.56) SLC1A3SLC1A2SLC1A1ADAMTS4MMP13
SCHEMBL27475768 0.82 CAPN1 (0.56) SLC1A3SLC1A2SLC1A1ADAMTS4MMP13
SCHEMBL7405654 0.81 SLC1A3 (0.60) ADAM17LARS1SLC1A3SLC1A2SLC1A1
SCHEMBL1770811 0.80 MMP1 (0.67) ADAM17LARS1SLC1A3SLC1A2SLC1A1
SCHEMBL12649188 0.80 MMP1 (0.67) ADAM17LARS1SLC1A3SLC1A2SLC1A1
SCHEMBL7769978 0.79 ALOX5AP (0.44) ADAM17CAPN1ALDH1A1
SCHEMBL3169303 0.77 ADAM17 (0.55) ADAM17LARS1SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0927716-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-05-07 EP disclosed
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0928786-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed